Suppression of matrix metalloproteinase-2-mediated cell invasion in U87MG, human glioma cells by anti-microtubule agent: in vitro study

被引:14
作者
Yoshida, D
Piepmeier, JM
Bergenheim, T
Henriksson, R
Teramoto, A
机构
[1] Nippon Med Sch, Dept Neurosurg, Tokyo 113, Japan
[2] Yale Univ, Sch Med, Dept Neurol Surg, New Haven, CT 06510 USA
[3] Umea Univ, Dept Neurosurg, Umea, Sweden
[4] Umea Univ, Dept Oncol, Umea, Sweden
关键词
estramustine; glioblastoma; Matrigel; matrix metalloproteinase; tumour invasion;
D O I
10.1038/bjc.1998.4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Because microtubules are important components of cell motility and intracellular transport, it is reasonable to propose that the depolymerizing effect of an antimicrotubule agent, estramustine, on glioma microtubules would modulate cell invasiveness. To determine whether matrix metalloproteinases, key factors in cell invasion, are affected by exposure to estramustine, a cell proliferation assay, a zymogram, a collagenolysis assay and a haptoinvasion assay were used in this study. The zymogram revealed that an activated (62 kDa) form of matrix metalloproteinase-2 diminished with increasing estramustine concentrations. The collagenolysis assay demonstrated approximately 2.5- to 21-fold lower rates of enzymatic activity suppressed by estramustine in a dose-dependent manner at estramustine concentrations of 1, 5, and 10 mu M, compared with the control group. On the haptoinvasion assay, no statistically significant difference was seen in the 0.5 mu M estramustine group, whereas 1-10 mu M estramustine groups revealed significant suppression of invasion from 6 to 24 h in a dose-dependent manner. The results suggest that estramustine suppresses the invasion of U87MG cells in vitro using the decreasing available matrix metalloproteinase-2, an effect caused by the disassembly of microtubules. Suppression of the infiltrative capacity of malignant glioma cells could be of significant value in the treatment of this disease.
引用
收藏
页码:21 / 25
页数:5
相关论文
共 40 条
[1]   EXPRESSION OF 72-KDA TYPE-IV COLLAGENASE AND INVASION ACTIVITY OF HUMAN GLIOMA-CELLS [J].
ABE, T ;
MORI, T ;
KOHNO, K ;
SEIKI, M ;
HAYAKAWA, T ;
WELGUS, HG ;
HORI, S ;
KUWANO, M .
CLINICAL & EXPERIMENTAL METASTASIS, 1994, 12 (04) :296-304
[2]  
ALBINI A, 1987, CANCER RES, V47, P3239
[3]   HUMAN ASTROCYTES PROLIFERATE IN RESPONSE TO TUMOR-NECROSIS-FACTOR-ALPHA [J].
BARNA, BP ;
ESTES, ML ;
JACOBS, BS ;
HUDSON, S ;
RANSOHOFF, RM .
JOURNAL OF NEUROIMMUNOLOGY, 1990, 30 (2-3) :239-243
[4]  
BERGENHEIM AT, 1994, CANCER RES, V54, P4974
[5]   UPTAKE AND RETENTION OF ESTRAMUSTINE AND THE PRESENCE OF ESTRAMUSTINE BINDING-PROTEIN IN MALIGNANT BRAIN-TUMORS IN HUMANS [J].
BERGENHEIM, AT ;
GUNNARSSON, PO ;
EDMAN, K ;
VONSCHOULTZ, E ;
HARIZ, MI ;
HENRIKSSON, R .
BRITISH JOURNAL OF CANCER, 1993, 67 (02) :358-361
[6]   C6 GLIOMA-ASTROCYTOMA CELL AND FETAL ASTROCYTE MIGRATION INTO ARTIFICIAL BASEMENT-MEMBRANE - A PERMISSIVE SUBSTRATE FOR NEURAL TUMORS BUT NOT FETAL ASTROCYTES [J].
BERNSTEIN, JJ ;
LAWS, ER ;
LEVINE, KV ;
WOOD, LR ;
TADVALKAR, G ;
GOLDBERG, WJ .
NEUROSURGERY, 1991, 28 (05) :652-658
[7]   MATRIX METALLOPROTEINASES - A REVIEW [J].
BIRKEDALHANSEN, H ;
MOORE, WGI ;
BODDEN, MK ;
WINDSOR, LJ ;
BIRKEDALHANSEN, B ;
DECARLO, A ;
ENGLER, JA .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :197-250
[8]   CYTOSKELETON ARCHITECTURE OF C6 RAT GLIOMA CELL SUBCLONES DIFFERING IN INTERMEDIATE FILAMENT PROTEIN EXPRESSION [J].
BOHN, W ;
ROSER, K ;
HOHENBERG, H ;
MANNWEILER, K ;
TRAUB, P .
JOURNAL OF STRUCTURAL BIOLOGY, 1993, 111 (01) :48-58
[9]  
CAMERON RS, 1994, J NEUROSCI, V14, P3139
[10]   CYTOSKELETON IN TFG-BETA-MODULATED AND BFGF-MODULATED ENDOTHELIAL MONOLAYER REPAIR [J].
COOMBER, BL .
EXPERIMENTAL CELL RESEARCH, 1991, 194 (01) :42-47